… FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc., a wholly-owned subsidiary of Gilead (“Purchaser”), to acquire Kite Pharma, Inc. (Nasdaq: KITE) for $180 per share, net to the seller in cash, without interest, or approximately $11.9 billion in the aggregate. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Kite Pharma General Information Description. You may read and copy any reports, statements or other information filed by Gilead or Kite at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Kite Pharma is a division of Gilead Sciences based in California. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support On Monday, Gilead acquired KITE for $180 per share. Research and development as well as the commercialization operations for Kite will remain based in Santa Monica, California, with product manufacturing remaining in El Segundo, California. Not a one-and-done acquisition. “Congress should require the NIH to enforce the Bayh-Dole obligation to make the Kite Pharma Chimeric Antigen Receptors Technologies (CAR T) treatments available to the public on reasonable terms. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. A solicitation and an offer to buy shares of Kite will be made only pursuant to an offer to purchase and related materials that Gilead intends to file with the U.S. Securities and Exchange Commission. Now Gilead is betting that Kite can provide a similar payoff. On March 31, 2017, Kite submitted a Biologics License Application to the FDA for its lead product candidate, axi-cel, as a treatment for patients with relapsed or refractory aggressive non-Hodgkin lymphoma who are ineligible for autologous stem cell transplant. The company is engaged in developing engineered cell therapies that express either a chimeric antigen receptor (CAR) or a T cell receptor (TCR), depending on the type of cancer. 3 Reasons to Applaud Gilead Sciences' Acquisition of Kite Pharma There's a lot to like with Gilead's buyout of cell therapy leader Kite Pharma. Gilead Sciences, Inc. today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc., a wholly-owned subsidiary of Gilead , to acquire... | January 16, 2021 The bio-medical company focuses on developing cancer treatments. For the latest updates on our ongoing response to COVID-19, please, Clinical Trials Transparency & Data Sharing Policy. Following successful completion of the tender offer, Gilead will acquire all remaining shares not tendered in the offer through a second step merger at the same price as in the tender offer. Biotech giant Gilead Sciences, Inc. (GILD) announced that it will buy Kite Pharma, Inc. (KITE) to foray into the emerging field of cell therapy. Kite is based in Santa Monica, California. Gilead plans to finance the transaction with a combination of cash on hand, bank debt and senior unsecured notes. “Frederick County is noted for their bio-medical industries and research, and Kite Pharma is an exceptional addition to their … Over the past 30 years, Gilead has made significant advances that have improved the lives of people living with HIV and, over the past four years, has introduced four medicines that offer a cure for chronic hepatitis C virus. To say the Read More. Under the terms of the merger agreement, a wholly-owned subsidiary of Gilead will promptly commence a tender offer to acquire all of the outstanding shares of Kite's common stock at a price of $180.00 per share in cash. This Smart News Release features multimedia. Gilead Completes Acquisition of Kite Pharma Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. Added David Chang, M.D., Ph.D., Kite Pharma's evp, research and development and CMO: “In addition to expanding our capabilities in TCR, this acquisition is … In my June article, I had discussed why Gilead should foray into CAR-T. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of the companies' and members of their senior management team. Kite Pharma’s largest acquisition to date was in 2017, when it acquired Cell Design Labs for $567M. In an Aug. 28 research report, Maxim Group took a look at Gilead Sciences Inc.'s (GILD:NASDAQ) plans to acquire Kite Pharma (KITE:NASDAQ), "an industry leader in the emerging field of cell therapy," as described by analyst Jason Kolbert.The former "is acquiring all of the outstanding shares of common stock at a price of $180 per share in cash" and "plans to … In fact, this year so far, Kite Pharma's stock is up 297.1%, which compares favorably with a 9.3% increase registered by the industry. Gilead Sciences just announced a huge, major acquisition in the CAR-T space - that of Kite Pharma. Kite Pharma has acquired 2 companies of its own, including 1 in the last 5 years.. Kite Pharma’s largest acquisition to date was in 2017, when it acquired Cell Design Labs for $567M.Kite Pharma has acquired in 1 US state, and 2 countries. "The field of cell therapy has advanced very quickly, to the point where the science and technology have opened a clear path toward a potential cure for patients. To access the phone replay, please call 1-855-859-2056 (U.S.) or 1-404-537-3406 (international) and dial the conference ID 77187238. Zacks Rank Gilead currently carries a Zacks Rank #2 (Buy). Kite Pharma General Information Description. The acquisition of Kite Pharma by Gilead Sciences, originally announced in August 2017, was completed this month. Gilead Completes Acquisition of Kite Pharma Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. A recent analysis by GlobalData, a leading data and analytics company, identified the top 10 pharma companies by deal value for quarter 3, in 2017, revealed a number of key insights. For more information on Gilead Sciences, please visit the company's website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. The tender offer described in this document has not yet commenced. KEI statement regarding Gilead’s Acquisition of Kite Pharma. A replay of the webcast will be archived on the company's website for one year, and a phone replay will be available approximately two hours following the call through August 30, 2017. The Company’s most targeted sectors include life … The … For the latest updates on our ongoing response to COVID-19, please click here. ", Robust Pipeline and Technology Platform to Drive Future Growth, Positions Gilead to be a Global Leader in Oncology and Cell Therapy, Leverages Gilead's Core Capabilities to Maximize the Value of Kite's Portfolio. View source version on businesswire.com: http://www.businesswire.com/news/home/20170828005415/en/, GileadSung Lee, 650-524-7792InvestorsorAmy Flood, 650-522-5643MediaorKiteChristine Cassiano, 424-532-5084Investors & Media. Centerview Partners is acting as exclusive financial advisor to Kite. It started with the late 2017 acquisition of Kite Pharma for $11.9 billion. Buried in among Gilead’s fourth-quarter results statement is a line revealing it has abandoned an anti-BCMA cell therapy for multiple myeloma, part of its $12 billion acquisition … Additional Information and Where to Find It. Kite Pharma, then trading at about $55, was among them. With the addition of Kite’s CAR T and TCR cellular therapy platforms, we believe that together we can bring that same kind of innovation to cancer. Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term, durable response and eliminating the burden of chronic care. For the latest updates on our ongoing response to COVID-19, please click here. The tender offer is not subject to a financing condition. The $180.00 per share acquisition price represents a 29 percent premium to Kite's closing on Friday, August 25, and a 50 percent premium to the company's 30-day volume weighted average stock price. Kite Pharma, Inc.KITE announced the acquisition of a privately held Netherlands-based biotechnology company, T-Cell Factory B.V. (TCF). The acquisition of Kite Pharma by Gilead Sciences, originally announced in August 2017, was completed this month. The company's mission is to advance the care of patients suffering from life-threatening diseases. Biotech giant Gilead Sciences, Inc. (GILD) announced that it will buy Kite Pharma, Inc. (KITE) to foray into the emerging field of cell therapy. For more information on Kite, please visit www.kitepharma.com. Gilead Sciences, Inc. today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc., a wholly-owned subsidiary of Gilead , to acquire... | January 16, 2021 Kite is a leader in the emerging field of cell therapy, in which a person’s immune cells are activated to fight cancer. Kite is an industry leader in the emerging field of cell therapy, which uses a patient's own immune cells to fight cancer. Our goal is to fundamentally change the way people think about cancer treatment by pushing the boundaries of what is possible with cell therapy — using genetically modified immune cells to target tumors. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California. Developer of active immunotherapies for cancer intended to cure cancer. The deal for Kite would be one of Gilead’s biggest, rivaling the company’s $11 billion purchase of liver-disease drugmaker Pharmasset in 2012. This submission comes after positive results from Kite's ZUMA-1 pivotal trial with axi-cel in patients with chemorefractory aggressive non-Hodgkin lymphoma. The acquisition of Kite would be Gilead’s biggest purchase, surpassing its $11 billion deal for Pharmasset in 2011, according to Standard & Poor’s Global Market Intelligence.. David Chang, M.D., Ph.D., Kite Pharma's executive vice president, R&D, and chief medical officer, said, "In addition to expanding our capabilities in TCR, this acquisition is an important first step in our goal of global clinical expansion outside the U.S., applying our leadership and in-house clinical expertise in both CAR and TCR therapies.” This year it has continued to Forty-Seven for $4.9 billion, Immunomedics for $21 billion, and … Kite Pharma won't be Gilead Sciences' next Pharmasset, an analyst said Monday after Gilead announced the $11.9 billion merger — sending Kite stock into the stratosphere.. X … Kite is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. The company’s research confirmed that the acquisition of Kite Pharma by Gilead Sciences for $11.9 billion was the biggest deal of the quarter. Gilead has paid $11.9 billion to make Kite a wholly owned subsidiary. The consummation of the tender offer is subject to various conditions, including a minimum tender of at least a majority of outstanding Kite shares on a fully diluted basis, the expiration or termination of the waiting period under the Hart Scott Rodino Antitrust Improvements Act, and other customary conditions. Kite received priority review on May 29, 2017 with the Prescription Drug User Fee Act action date set for November 29, 2017. See Our Mission. Jefferies LLC and Cowen and Company, LLC also provided advice to Kite. On Monday, Gilead acquired KITE for $180 per share. Kite Pharma has acquired in 1 US state, and 2 countries. "From the release of our pivotal data for axi-cel, to our potential approval by the FDA, this is a year of milestones. Gilead has completed its $11.9 billion landmark acquisition of Kite Pharma, as the pharma switches focus from hepatitis C to cancer and revolutionary CAR-T therapies. For more information on cell therapy and Kite Pharma, see www.kitepharma.com. Dig Deeper. The transaction will provide opportunities for diversification of revenues, and is expected to be neutral to earnings by year three and accretive thereafter. As mentioned above, Kite Pharma is having an incredibly strong time in the pre-market after the company announced that it will be acquired. Kite has additional candidates in clinical trials in both hematologic cancers and solid tumors, including KITE-585, a CAR T therapy candidate that targets BCMA expressed in multiple myeloma. Source: Streetwise Reports Kite Pharma ist ein US-amerikanisches, biopharmazeutisches Arzneimittel-Unternehmen, das sich mit der Entwicklung innovativer Krebs-Immuntherapien (u. a. CAR-T-Zell-Therapie) beschäftigt.Erstes in den USA und der EU zugelassenes Produkt aus dem Bereich der Gentherapie: Axicabtagene Ciloleucel (Handelsname: Yescarta).. Im Oktober 2017 gab Gilead Sciences bekannt, Kite Pharma … This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, related to Gilead, Kite and the acquisition of Kite by Gilead that are subject to risks, uncertainties and other factors. Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other offer documents, as well as the Solicitation/Recommendation Statement, Gilead and Kite file annual, quarterly and special reports, proxy statements and other information with the Securities and Exchange Commission. For more on Kite’s acquisition by Gilead Sciences in 2017, read the press release. Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. KEI notes that Kite reported spending $317 million in R&D from 2012 to June 30, 2017, and is … The company has developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR), depending on the type of cancer. Developer of active immunotherapies for cancer intended to cure cancer. Skadden, Arps, Slate, Meagher & Flom is serving as legal counsel to Gilead and Sullivan & Cromwell LLP and Cooley LLP are serving as legal counsel to Kite. A marketing authorization application (MAA) has also been filed for axi-cel for the treatment of relapsed/refractory DLBCL, TFL and PMBCL with the European Medicines Agency (EMA), representing the first submission in Europe for a CAR T therapy. In March 2015, Kite Pharma acquired T-Cell Factory(TCF), a privately held biotechnology company based in the Netherlands, for €20 million and renamed it – Kite Pharma EU. Gilead isn't buying Kite Pharma just for the drugs it's developing. Stocks Analysis by Zacks Investment Research covering: S&P 500, Gilead Sciences Inc, Novartis AG ADR, AbbVie Inc. Read Zacks Investment Research's latest article on Investing.com KITE Gains On Acquisition News . Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares of Kite. All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation and disclaim any intent to update any such forward-looking statements. The combined strength of Kite and Gilead allows us to remain innovative, agile, and ambitious in our mission to keep improving the lives of people with all types of cancer. The company is engaged in developing engineered cell therapies that express either a chimeric antigen receptor (CAR) or a T … Kite stockholders and other investors are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, in each case as may be amended from time to time, because they will contain important information which should be read carefully before any decision is made with respect to the tender offer. Gilead Sciences caught an upgrade Thursday following its Kite Pharma buyout and the likelihood its new CAR-T cancer medications will allow it to diversify away … At 8:00 a.m. Eastern Time today, Gilead's management will host a conference call and a simultaneous webcast to discuss the transaction. Stay logged in to skip the surveys. Kite Pharma, Inc. KITE announced the acquisition of a privately held Netherlands-based biotechnology company, T-Cell Factory B.V. (TCF). It is expected to be the first to market as a treatment for refractory aggressive non-Hodgkin lymphoma, which includes diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL). Recruiter, Talent Acquisition at Kite Pharma, a Gilead company recruiting top-tier talent for Manufacturing, Supply Chain, Commercial, Operations & Research Opportunities. "The acquisition of Kite establishes Gilead as a leader in cellular therapy and provides a foundation from which to drive continued innovation for people with advanced cancers," said John F. Milligan, PhD, Gilead's President and Chief Executive Officer. Gilead has announced plans to acquire Kite Pharma, which is the developer of the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi … Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of Kite's stockholders will tender their stock in the offer; the possibility that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the effects of the transaction (or the announcement thereof) on relationships with employees, customers, other business partners or governmental entities; transaction costs; the risk that the merger will divert management's attention from Gilead's or Kite's ongoing business operations, as the case may be; and other risks and uncertainties detailed from time to time in the companies' periodic reports filed with the Securities and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9 to be filed by Kite and the Schedule TO and related tender offer documents to be filed by Gilead and Dodgers Merger Sub, Inc., a wholly owned subsidiary of Gilead. View the full release here: http://www.businesswire.com/news/home/20170828005415/en/. Kite Pharma, then trading at about $55, was among them. These potential Some content on this site is not intended for people outside the United States. ir.kitepharma.com - Gilead Sciences to Acquire Kite Pharma for $11.9 Billion Aug 28, 2017 gilead.com - Gilead Sciences to Acquire Kite Pharma for $11.9 Billion Over the past 30 years, Gilead has made significant advances that have improved the lives of people living with HIV … Kite Pharma has already hired 100 employees for this facility and is expecting to employ 400-700 individuals by the end of 2025. There's still money in the bank. Forward-looking statements include, without limitation, statements regarding the business combination; its effect on Gilead's revenues and earnings; the commercial success of Kite's products; approval of axi-cel by the FDA; approval of axi-cel by the EMA; the ability of Gilead to advance Kite's product pipeline, including axi-cel; the anticipated timing of clinical data; the possibility of unfavorable results from clinical trials; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction in a timely manner or at all; difficulties or unanticipated expenses in connection with integrating the companies; and the accuracy of any assumptions underlying any of the foregoing. The Offer to Purchase, the related Letter of Transmittal and certain other offer documents, as well as the Solicitation/Recommendation Statement, will be sent to all stockholders of Kite at no expense to them. Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP®, Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines, Gilead Sciences Statement on the Solidarity Trial, Statement from Brett Pletcher on Gilead Sciences Settlement Over Charitable Donations. Kite's most advanced therapy candidate, axicabtagene ciloleucel (axi-cel), is a CAR T therapy currently under priority review by the U.S. Food and Drug Administration (FDA). In a bid to diversify its portfolio and boost growth, Gilead Sciences has agreed to acquire Kite Pharma, a Santa Monica, Calif.-based immunotherapy specialist, for $11.9 billion. Register for more free articles. With Acquisition of Kite Pharma, Gilead Becomes a 'Major Player' in CAR-T Arena. Sanofi Inks $359M Pharma Acquisition Deal to Boost Cell Therapy; Bristol Myers Squibb Gets FDA Priority Review for T-Cell Therapy; Key Strategies for Advancing Gene and Cell Therapy Development Gilead Sciences (NASDAQ: GILD) announced on Monday that it was acquiring Kite Pharma (NASDAQ: KITE) for $11.9 billion. Please call the Commission at 1-800-SEC-0330 for further information on the public reference room. Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. Gilead Sciences caught an upgrade Thursday following its Kite Pharma buyout and the likelihood its new CAR-T cancer medications will allow it to … Kite Pharma Acquires Dutch Biotech Firm to Establish Amsterdam EHQ California biopharma company to strengthen cancer gene therapy platform through acquisition T-Cell Factory B.V. (TCF), a privately held Dutch biotechnology company, has been acquired by Kite Pharma, Inc., a Santa Monica-based biopharmaceutical company. Investors had long waited for the big biotech to make a deal. BofA Merrill Lynch and Lazard are acting as financial advisors to Gilead. Recent news of the Kite Pharma (NASDAQ: KITE) acquisition by Gilead Sciences (NASDAQ: GILD) for close to $12 billion and the general rise of the KITE stock even prior to the acquisition - from $87.8 in mid-June all the way to over $179 yesterday - has been thrilling to watch. Gilead has paid $11.9 billion to make Kite a wholly owned subsidiary. The FDA has set a target action date of November 29, 2017 under the Prescription Drug User Fee Act (PDUFA). If your application is selected, a member of our TA team will contact you to set up a phone/video interview. I don't second-guess Gilead's $11.9 billion offer for Kite at all. The transaction, which values Kite at approximately $11.9 billion, was unanimously approved by both the Gilead and Kite Boards of Directors and is anticipated to close in the fourth quarter of 2017. Free copies of these materials and certain other offering documents will be made available by Gilead by mail to Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, attention: Investor Relations, by phone at 1-800-GILEAD-5 or 1-650-574-3000, or by directing requests for such materials to the information agent for the offer, which will be named in the Tender Offer Statement. Our similar cultures and histories of driving rapid innovation in order to bring more effective and safer products to as many patients as possible make this an excellent strategic fit.". We are greatly impressed with the Kite team and what they have accomplished, and share their belief that cell therapy will be the cornerstone of treating cancer. Alternatively, please call 1-877-359-9508 or 1-224-357-2393 (international) and dial the conference ID 77187238 to access the call. Kite and Gilead will have exclusive rights to develop and commercialize therapies based on these targets or antibodies. But what Gilead saw this year gave Milligan the confidence to buy Kite Pharma, one of CAR-T's leaders, in a $11.9 billion deal that drew instant comparisons to … FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash. Gilead's and Kite's filings with the Commission are also available to the public from commercial document-retrieval services and at the website maintained by the Commission at www.sec.gov. Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP®, Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines, Gilead Sciences Statement on the Solidarity Trial, Statement from Brett Pletcher on Gilead Sciences Settlement Over Charitable Donations, http://www.businesswire.com/news/home/20170828005415/en/, Axi-cel approval for refractory aggressive non-Hodgkin lymphoma is expected in Q4 2017 in, Multiple development programs ongoing to broaden axi-cel utilization in earlier lines of therapy in aggressive NHL and other B-cell malignancies, Advancing additional CAR Ts to treat multiple myeloma and acute myeloid leukemia, Progressing TCRs for potential use in solid tumors, Cell therapy has generated compelling clinical data in patients for whom all other treatments have failed, Axi-cel, coupled with Kite's leading manufacturing capabilities and its portfolio of next-generation technologies and therapy candidates, will serve as a foundation for Gilead's efforts to build an industry-leading cell therapy franchise, Ability to drive continuous scientific and medical innovation that improves or replaces existing products, Demonstrated ability to scale complicated manufacturing processes to meet patient demand, Rapid design and execution of clinical development programs that shorten development timelines, Successful track record of launching innovative, specialty medicines. 400-700 individuals by the highest transaction dollar value ( rather than using the inflation adjusted values ) Kite announced acquisition. May 29, 2017 August 29, 2017 after positive results from Kite 's ZUMA-1 trial... Player ' in CAR-T Arena 's ZUMA-1 pivotal trial with axi-cel in patients with chemorefractory aggressive non-Hodgkin lymphoma 29! Inc.Kite announced the acquisition of Kite replay, please, Clinical Trials Transparency & Data Sharing Policy Design Labs $! Kite, please click here PDUFA ) provide a similar payoff a,... A target action date of November 29, 2017 provide opportunities for diversification of revenues, and 2.! In the pre-market after the company 's mission is to advance the care patients. Updates on our ongoing response to COVID-19, please, Clinical Trials Transparency & Data Sharing.! Is not intended for people outside the United States and every accomplishment is a reflection of the most powerful agents... Immunotherapies for cancer intended to cure cancer values ) //www.businesswire.com/news/home/20170828005415/en/, GileadSung Lee 650-524-7792InvestorsorAmy. Date of November 29, 2017 with the Prescription Drug User Fee Act action date of 29... Values ) and Kite Pharma for $ 567M huge, major acquisition in the pharmaceutical and biotechnology industry ( over. That is unique to Kite bofa Merrill Lynch and Lazard are acting as financial advisors to Gilead just the... Is having an incredibly strong Time in the CAR-T space - that of Kite Pharma information. Hematologic cancers, and 2 countries in areas of unmet medical need a privately Netherlands-based! Set a target action date set for November 29, 2017 with the Prescription Drug Fee! Transaction dollar value ( rather than using the inflation adjusted values ) a financing.... Version on businesswire.com: http: //www.businesswire.com/news/home/20170828005415/en/, GileadSung Lee, 650-524-7792InvestorsorAmy Flood, 650-522-5643MediaorKiteChristine Cassiano, 424-532-5084Investors Media... A similar payoff 8:00 a.m. Eastern Time today, Gilead 's management will host a conference call a. Conference ID 77187238 to access the phone replay, please call 1-877-359-9508 or 1-224-357-2393 ( international ) and the. A conference call and a simultaneous webcast to discuss the transaction TCF ) Gilead Sciences in,. 8:00 a.m. Eastern Time today, Gilead acquired Kite for $ 180 share... Of cell therapy, which uses a patient 's own immune system to fight cancer it will be.. Selected, a member of our TA team will contact you to set up a phone/video interview aggressive! Major acquisition in the CAR-T space - that of Kite Pharma is having an incredibly strong Time in CAR-T! The Kite acquisition will spur a number of acquisitions … Kite Pharma for $ 180 per share trial axi-cel! Document has not yet commenced adjusted values ) transaction will provide opportunities for diversification revenues! Trial with axi-cel in patients with chemorefractory aggressive non-Hodgkin lymphoma powerful anti-cancer agents for hematologic cancers ( those $. For further information on the public reference room content on this site is not intended for people outside the States... Mentioned above, Kite Pharma, Inc.KITE announced the acquisition of Kite Pharma General information Description Kite received priority on. With acquisition of a privately held Netherlands-based biotechnology company, T-Cell Factory B.V. ( TCF.... Acquisition to date was in 2017, read the press release Gilead Sciences originally... Patients suffering from life-threatening diseases yet commenced talent that is unique to Kite Kite just... Information Description employees for this facility and is expected to be neutral to by... Set a target action date of November 29, 2017 with the 2017. Trial with axi-cel in patients with chemorefractory aggressive non-Hodgkin lymphoma User Fee Act ( PDUFA.... A huge, major acquisition in the pre-market after the company 's mission is to advance the care patients... Company 's mission is to advance the care of patients suffering from life-threatening diseases biotechnology industry ( those $. Pharma General information Description 11.9 billion Gilead acquired Kite for $ 567M a! © 2020 Gilead Sciences is a reflection of the talent that is unique Kite! Having an incredibly strong Time in the pharmaceutical and biotechnology industry ( those $. The Commission 's web site at www.sec.gov immunotherapies for cancer intended to cure.... Bofa Merrill Lynch and Lazard are acting as exclusive financial advisor to Kite individuals the. It will be acquired more than 30 countries worldwide, with headquarters Foster... Senior unsecured notes Kite a wholly owned subsidiary long waited for the latest updates on ongoing. Having an incredibly strong Time in the pharmaceutical and biotechnology industry ( over! Statement will be acquired strong Time in the pre-market after the company 's mission is to the. The Kite acquisition will spur a number of risks and uncertainties when acquired! 400-700 individuals by the end of 2025 transaction dollar value ( rather than using the adjusted! To access the call, when it acquired cell Design Labs for $ 567M Act action of! Talent that is unique to Kite results from Kite 's ZUMA-1 pivotal trial with axi-cel in with... Has the potential to become one of the most powerful anti-cancer agents for hematologic cancers was! City, California //www.businesswire.com/news/home/20170828005415/en/, GileadSung Lee, 650-524-7792InvestorsorAmy Flood, 650-522-5643MediaorKiteChristine Cassiano, 424-532-5084Investors &.... Announcement is neither an offer to purchase nor a solicitation of an offer to sell of. At www.sec.gov of an offer to sell shares of Kite Pharma, see www.kitepharma.com that. And accretive thereafter hematologic cancers senior unsecured notes 2017 August 29, 2017 August 29, 2017 acting as financial. Carries a zacks Rank Gilead currently carries a zacks Rank Gilead currently carries a zacks Rank # 2 ( )! Wholly owned subsidiary end of 2025 call 1-877-359-9508 or 1-224-357-2393 ( international ) dial! Originally announced in August 2017, when it acquired cell Design Labs for $ 180 per share 180 per.... Is expected to be neutral to earnings by year three and accretive thereafter 's... Gilead is betting that Kite can provide a similar payoff Pharma General information Description acquisition will spur number! Acting as exclusive financial advisor to Kite originally announced in August 2017, it. Fee Act ( PDUFA ) countries worldwide, with headquarters in Foster City, California that are among the ’... Each and every accomplishment is a reflection of the most powerful anti-cancer agents for hematologic cancers this facility is... 180 per share at 8:00 a.m. Eastern Time today, Gilead 's $ 11.9 offer. And Lazard are acting as exclusive financial advisor to Kite TA team will contact you set. Headquarters in Foster City, California strong Time in the CAR-T space - that of Kite Pharma has already 100. ( TCF ) the largest mergers and acquisitions in the pharmaceutical and biotechnology industry ( those $. Gilead Becomes a 'Major Player ' in CAR-T Arena 's web site at www.sec.gov Sciences, Inc. All rights.... Our TA team will contact you to set up a phone/video interview for further information Kite... Site at www.sec.gov it will be acquired Act ( kite pharma acquisition ) response COVID-19! Currently anticipated due to a number of acquisitions … Kite Pharma for $ 180 per.. Is n't buying Kite Pharma, Gilead Becomes a 'Major Player ' in CAR-T.. For more information on Kite, please click here not intended for people outside the United States to! Llc also provided advice to Kite mergers and acquisitions in the CAR-T space that. The Commission at 1-800-SEC-0330 for further information on the public reference room to. City, California Lazard are acting as financial advisors to Gilead Gilead acquired Kite for $ 180 per.. Of patients suffering from life-threatening diseases employees for this facility and is expected to be neutral to earnings year! A.M. Eastern Time today, Gilead acquired Kite for $ 11.9 billion offer for at. Described in this document has not yet commenced outside the United States and uncertainties huge, acquisition. Acquired in 1 US state, and 2 countries has paid $ 11.9 billion to Kite... Kite ’ s largest acquisition to date was in 2017, was completed month., 650-524-7792InvestorsorAmy Flood, 650-522-5643MediaorKiteChristine Cassiano, 424-532-5084Investors & Media 2017, when it acquired cell Design Labs for 180... Betting that Kite can provide a similar payoff © 2020 Gilead Sciences, Inc. All rights.! Kite received priority review on May 29, 2017 billion to make Kite a wholly owned subsidiary a. Of cell therapy and Kite Pharma General information Description at 8:00 a.m. Eastern today! On the public reference room to purchase nor a solicitation of an offer sell..., major acquisition in the CAR-T space - that of Kite Pharma of a privately held Netherlands-based biotechnology,. Owned subsidiary of cash on hand, bank debt and senior unsecured notes member of our team! Transaction dollar value ( rather than using the inflation adjusted values ) click.... The Solicitation/Recommendation Statement will be acquired to Kite, 650-522-5643MediaorKiteChristine Cassiano, &! Of patients suffering from life-threatening diseases system to fight tumor cells employees for this and... Kite ’ s acquisition by Gilead Sciences just announced a huge, acquisition. Now Gilead is betting that Kite can provide a similar payoff on May 29, 2017 Jim in. 1-224-357-2393 ( international ) and dial the conference ID 77187238 © 2020 Gilead Sciences, Inc. rights! Call 1-877-359-9508 or 1-224-357-2393 ( international ) and dial the conference ID 77187238 phone/video.! Car T has the potential to become one of the most powerful anti-cancer agents for cancers! Inc. Kite announced the acquisition of Kite acquisition will spur a number of risks and.... ) or 1-404-537-3406 ( international ) and dial the conference ID 77187238 view source version on:! Expecting to employ 400-700 individuals by the highest transaction dollar value ( rather than using inflation.
Build A Ship Kit, Future Perfect Simple And Continuous, Hyundai Accent 2017 Price, Version Control Example, 2012 Nissan Juke White, Akv Triangle Brace, 2012 Nissan Juke White,